Table 1.
Cohort 1 (n=78) | Cohort 2 (n=322) | |
Age at start | ||
Mean (range in years) | 63.6 (35–78) | 64.7 (29–85) |
n | % | n | % | |
Sex | ||||
Male | 48 | 61.5 | 202 | 62.7 |
Female | 30 | 38.5 | 120 | 37.3 |
Primary tumor | ||||
Adenocarcinoma | 52 | 66.7 | 200 | 62.1 |
Squamous cell carcinoma | 17 | 21.8 | 96 | 29.8 |
Large cell carcinoma | – | – | 22 | 6.8 |
Lung cancer with unknown pathology | 9 | 11.5 | 4 | 1.2 |
WHO PS | ||||
0 | 18 | 23.1 | 54 | 16.8 |
1 | 39 | 50.0 | 188 | 58.4 |
2 | 1 | 1.3 | 7 | 2.2 |
3 | – | – | 1 | 0.3 |
Unknown | 20 | 25.6 | 72 | 22.4 |
Prior lines | ||||
0 | 2 | 2.6 | 1 | 0.3 |
1 | 60 | 76.9 | 217 | 67.4 |
2 | 13 | 16.7 | 82 | 25.5 |
3 | 2 | 2.6 | 15 | 4.7 |
4 | 1 | 1.3 | 6 | 1.9 |
5 | – | – | 1 | 0.3 |
Smoking status | ||||
History or current smoker | 56 | 71.8 | 238 | 73.9 |
Never smoker | 8 | 10.3 | 20 | 6.2 |
Unknown | 14 | 17.9 | 64 | 19.9 |
Ethnicity | ||||
Caucasian | 74 | 94.9 | 308 | 95 |
Other | 4 | 5.1 | 5 | 2 |
Unknown | 0 | – | 9 | 3 |
Baseline characteristics of NSCLC cohort 1 and cohort 2. 16.5% of the patients (n=53) from cohort 1 were overlapping with cohort 2.
NSCLC, non-small-cell lung cancer; WHO PS, WHO performance status.